The LEADER trial with liraglutide reported a reduction in MACE (HR 0.87), while the REWIND trial with dulaglutide demonstrated an HR of 0.88
Typically, most patients notice visible improvements in skin tone within 4 to 6 weeks after starting injections
The goal for all types is to get the dose that keeps you losing steady weight with the fewest side effects
Here's what actually keeps a GLP-1 patient on program for 6 to 12 months: A structured check-in cadence, not "see you next month" Weigh-in and measurement touchpoints that create accountability between visits Automated encouragement timed to hit right before the typical plateau Proactive outreach before a patient's usual drop-off window, not after they've gone quiet Flexible, one-tap rebooking instead of a phone call nobody has time to make None of this is about better medicine
Including compounds like Dihexa for cognitive research and Tesofensine for metabolic studies
Similarly, if a patient on semaglutide is prescribed a new anticoagulant or antiplatelet medication, both prescribers should be informed to ensure coordinated care